Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323824 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL5315326 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL1172743 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL3359435 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL2034678 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL8295172 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL323823 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL4126470 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| Hydrochloric Acid SCHEMBL5089207 | 0.98 | FFAR1 (0.68) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| Hydrochloric Acid SCHEMBL5089203 | 0.98 | FFAR1 (0.68) | FFAR1HDAC4ALDH1A1SLC9A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581217-A4 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1581217-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2004041277-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | claimed |
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-8324245-B2 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20110105747-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20080312221-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-12-18 | — | — | US | disclosed |
| WO-2008115154-A1 | CATALYST IMMOBILIZATION ON SILICEOUS MESOCELLULAR FOAM VIA CLICK CHEMISTRY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2008-09-25 | — | — | WO | disclosed |
| US-7425564-B2 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | FFAR1 4075/4885HDAC4 1371/4885ALDH1A1 1370/4885 |
| US-20080312221-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | NR1H2, NR1H3, NR1H4 | FFAR1 98/4885HDAC4 293/4885ALDH1A1 3550/4885 |
| US-20110105747-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | NR1H2, NR1H3, NR1H4 | FFAR1 89/4885HDAC4 356/4885ALDH1A1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.